Showing results (51-60 of 1,205) with videos related to
Sort By:
Pageof 121
Molecular Aspects of Medicine|December 17, 2013
Clinical application of transcriptional activators of bile salt transportersAnna Baghdasaryan, Peter Chiba, Michael TraunerSeminars in Liver Disease|November 14, 2013
Bile acid-mediated control of liver triglyceridesClaudia Fuchs, Thierry Claudel, Michael TraunerNature Clinical Practice. Gastroenterology & Hepatology|September 30, 2006
Mechanisms of disease: mechanisms and clinical implications of cholestasis in sepsisAndreas Geier, Peter Fickert, Michael TraunerDigestive Diseases (Basel, Switzerland)|March 2, 2017
Nor-Ursodeoxycholic Acid as a Novel Therapeutic Approach for Cholestatic and Metabolic Liver DiseasesEmina Halilbasic, Daniel Steinacher, Michael TraunerDigestive Diseases (Basel, Switzerland)|March 2, 2017
Therapeutic Mechanisms of Bile Acids and Nor-Ursodeoxycholic Acid in Non-Alcoholic Fatty Liver DiseaseDaniel Steinacher, Thierry Claudel, Michael TraunerAlimentary Pharmacology & Therapeutics|September 23, 2021
Review article: therapeutic aspects of bile acid signalling in the gut-liver axisBenedikt Simbrunner, Michael Trauner, Thomas ReibergerJournal of Hepatology|August 14, 2012
Bile acid transporters and regulatory nuclear receptors in the liver and beyondEmina Halilbasic, Thierry Claudel, Michael TraunerJournal of Hepatology|September 16, 2003
Role of nuclear bile acid receptor, FXR, in adaptive ABC transporter regulation by cholic and ursodeoxycholic acid in mouse liver, kidney and intestineGernot Zollner, Peter Fickert, Andrea Fuchsbichler, et al.Journal of Hepatology|June 30, 2019
Obeticholic acid may increase the risk of gallstone formation in susceptible patientsSamer Al-Dury, Annika Wahlström, Katrin Panzitt, et al.Journal of Hepatology|November 18, 2005
Successful treatment of severe unconjugated hyperbilirubinemia via induction of UGT1A1 by rifampicinEwa Ellis, Martin Wagner, Frank Lammert, et al.Pageof 121